Grifols, S.A. (GRFS)
NASDAQ: GRFS · Real-Time Price · USD
8.63
-0.59 (-6.40%)
Nov 5, 2025, 4:00 PM EST - Market closed
Grifols Employees
Grifols had 23,737 employees as of December 31, 2023. The number of employees decreased by 2,577 or -9.79% compared to the previous year.
Employees
23,737
Change (1Y)
-2,577
Growth (1Y)
-9.79%
Revenue / Employee
$368,380
Profits / Employee
$14,716
Market Cap
7.47B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 23,737 | -2,577 | -9.79% |
| Dec 31, 2022 | 26,314 | 3,080 | 13.26% |
| Dec 31, 2021 | 23,234 | -421 | -1.78% |
| Dec 31, 2020 | 23,655 | -348 | -1.45% |
| Dec 31, 2019 | 24,003 | 2,773 | 13.06% |
| Dec 31, 2018 | 21,230 | 2,934 | 16.04% |
| Dec 31, 2017 | 18,296 | 3,419 | 22.98% |
| Dec 31, 2016 | 14,877 | 140 | 0.95% |
| Dec 31, 2015 | 14,737 | 757 | 5.41% |
| Dec 31, 2014 | 13,980 | 2,201 | 18.69% |
| Dec 31, 2013 | 11,779 | 671 | 6.04% |
| Dec 31, 2012 | 11,108 | -122 | -1.09% |
| Dec 31, 2011 | 11,230 | 5,262 | 88.17% |
| Dec 31, 2010 | 5,968 | -16 | -0.27% |
| Dec 31, 2009 | 5,984 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GRFS News
- 12 hours ago - Grifols, S.A. (GIKLY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Top Biotech Stocks Riding The Rally - Seeking Alpha
- 6 days ago - 4 Best Value And Growth Stocks (Yes, They Can Coexist) - Seeking Alpha
- 27 days ago - Spanish court summons Gotham City founder in Grifols share price probe - Reuters
- 4 weeks ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 4 weeks ago - Grifols: Significant Upside Likely Materializing - Seeking Alpha
- 5 months ago - XL-protein grants worldwide license to Grifols to develop a biopharmaceutical using PASylation® technology - GlobeNewsWire
- 5 months ago - Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting - Business Wire